Discount double whammy could cost €2.6bn: industry needs voice on German price body
This article was originally published in Scrip
Increased mandatory discounts have this year hit pharmaceutical companies twice as hard as expected. In the first half of 2011 alone, the German government saved what it intended to save through the discounts over a 12 month period, says Dr Alexander Natz, Brussels representative for the BPI, the German association of mid-sized pharmaceutical companies. Dr Natz also believes that the German reimbursement body, the G-BA, needs a voice from the pharmaceutical industry if it is to reflect thinking across the spectrum of healthcare.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.